131I whole-body scan or 18FDG PET/CT for patients with elevated thyroglobulin and negative ultrasound?

[1]  M. Salvatori,et al.  The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview , 2013, European Archives of Oto-Rhino-Laryngology.

[2]  L. Ceriani,et al.  The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Aggressive Histological Subtypes of Thyroid Cancer: An Overview , 2013, International journal of endocrinology.

[3]  P. Trimboli,et al.  Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  P. Rosário,et al.  Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. , 2012, Thyroid : official journal of the American Thyroid Association.

[5]  F. Bidault,et al.  Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. , 2012, Thyroid : official journal of the American Thyroid Association.

[6]  R. Tuttle,et al.  Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[7]  A. Bockisch,et al.  18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  L. Ceriani,et al.  Relationship between serum thyroglobulin and 18FDG‐PET/CT in 131I‐negative differentiated thyroid carcinomas , 2012, Head & neck.

[9]  S. Iwano,et al.  FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer , 2012, Annals of Nuclear Medicine.

[10]  A. Bockisch,et al.  Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma , 2012, Clinical nuclear medicine.

[11]  L. Giovanella.  Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas , 2012, Expert review of endocrinology & metabolism.

[12]  S. Fujita,et al.  Comparison of diagnostic and prognostic capabilities of 18F-FDG-PET/CT, 131I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer , 2011, Japanese Journal of Radiology.

[13]  Jung-Joon Min,et al.  Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  H. Schöder,et al.  Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging. , 2011, Seminars in nuclear medicine.

[15]  A. Piccardo,et al.  Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan? , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[16]  S. Kanazawa,et al.  The Local Efficacy of I-131 for F-18 FDG PET Positive Lesions in Patients With Recurrent or Metastatic Thyroid Carcinomas , 2011, Clinical nuclear medicine.

[17]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[18]  F. Bidault,et al.  18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Yanyan Gao,et al.  The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. , 2010, European journal of endocrinology.

[20]  S. Baba,et al.  Detection of Residual Lymph Node Metastases in High-Risk Papillary Thyroid Cancer Patients Receiving Adjuvant I-131 Therapy: The Usefulness of F-18 FDG PET/CT , 2010, Clinical nuclear medicine.

[21]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[22]  Shu-ye Yang,et al.  Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis , 2009, Nuclear medicine communications.

[23]  A. Alzahrani,et al.  The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer. , 2008, European journal of endocrinology.

[24]  M. Salvatore,et al.  Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose , 2008, La radiologia medica.

[25]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[26]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  T. Saga,et al.  Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  L. Duntas,et al.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. , 2004, European journal of endocrinology.

[29]  Eun Sook Kim,et al.  Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole‐body scan: comparative study , 2003, Clinical endocrinology.

[30]  Ren-Shyan Liu,et al.  Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer. , 2002, Journal of the Formosan Medical Association = Taiwan yi zhi.

[31]  A. Pinchera,et al.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.

[32]  R. Kloos,et al.  Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? , 2002, The Journal of clinical endocrinology and metabolism.

[33]  R. Kloos,et al.  Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer , 2001 .

[34]  T. Shiga,et al.  Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[36]  E. Baudin,et al.  131I therapy for elevated thyroglobulin levels. , 1997, Thyroid : official journal of the American Thyroid Association.

[37]  M. Schlumberger,et al.  Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. , 1996, European journal of cancer.

[38]  J. Hanke,et al.  [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.

[39]  K. Ain,et al.  Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. , 1995, The Journal of clinical endocrinology and metabolism.

[40]  P. Ladenson,et al.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[41]  M. Schlumberger,et al.  Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  A. Pinchera,et al.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  M. Ashcraft,et al.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. , 1981, The American journal of medicine.

[44]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.

[45]  W. Müller-Schauenburg,et al.  18FDG-Ganzkörper-PET bei differenzierten Schilddrüsenkarzinomen , 1995, Nuklearmedizin.